RARE Stock Overview
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Ultragenyx Pharmaceutical Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$56.26 |
52 Week High | US$60.37 |
52 Week Low | US$31.52 |
Beta | 0.57 |
11 Month Change | -4.24% |
3 Month Change | 26.54% |
1 Year Change | 69.87% |
33 Year Change | -28.07% |
5 Year Change | 37.42% |
Change since IPO | 33.16% |
Recent News & Updates
Recent updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Shareholder Returns
RARE | US Biotechs | US Market | |
---|---|---|---|
7D | 2.1% | 0.6% | 0.8% |
1Y | 69.9% | 27.4% | 38.3% |
Return vs Industry: RARE exceeded the US Biotechs industry which returned 26.9% over the past year.
Return vs Market: RARE exceeded the US Market which returned 36% over the past year.
Price Volatility
RARE volatility | |
---|---|
RARE Average Weekly Movement | 5.7% |
Biotechs Industry Average Movement | 9.7% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RARE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RARE's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 1,276 | Emil Kakkis | www.ultragenyx.com |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. Fundamentals Summary
RARE fundamental statistics | |
---|---|
Market cap | US$5.18b |
Earnings (TTM) | -US$585.12m |
Revenue (TTM) | US$481.30m |
10.8x
P/S Ratio-8.9x
P/E RatioIs RARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RARE income statement (TTM) | |
---|---|
Revenue | US$481.30m |
Cost of Revenue | US$719.64m |
Gross Profit | -US$238.34m |
Other Expenses | US$346.78m |
Earnings | -US$585.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -6.35 |
Gross Margin | -49.52% |
Net Profit Margin | -121.57% |
Debt/Equity Ratio | 205.6% |
How did RARE perform over the long term?
See historical performance and comparison